Supreme Court Questions Rs 27,000 MRP on Rs 3,000 Cancer Drug

The Supreme Court criticized the large price gap between retailer cost and patient charges for medicines, highlighting a cancer drug sold to retailers at Rs 3,000 but with an MRP of Rs 27,000. The Court questioned the absence of a uniform pricing framework and suggested a 16% margin cap. It also raised concerns about corporate hospitals forcing patients to buy overpriced medicines from in-house pharmacies.

Tip: use ↑ / ↓ (or j / k) to move between stories.